Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 3 of 3

Publication Record


Chemotherapy-induced splenic volume increase is independently associated with major complications after hepatic resection for metastatic colorectal cancer.
Simpson AL, Leal JN, Pugalenthi A, Allen PJ, DeMatteo RP, Fong Y, Gönen M, Jarnagin WR, Kingham TP, Miga MI, Shia J, Weiser MR, D'Angelica MI
(2015) J Am Coll Surg 220: 271-80
MeSH Terms: Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Case-Control Studies, Chemotherapy, Adjuvant, Colorectal Neoplasms, Female, Follow-Up Studies, Hepatectomy, Humans, Liver Neoplasms, Male, Middle Aged, Neoadjuvant Therapy, Postoperative Complications, Retrospective Studies, Risk Factors, Single-Blind Method, Splenomegaly, Treatment Outcome
Show Abstract · Added February 12, 2015
BACKGROUND - In patients with colorectal cancer liver metastases (CRCLM), chemotherapy-induced hepatic injury is associated with increased splenic volume, thrombocytopenia, and decreased long-term survival. The current study investigates the relationship between change in splenic volume after preoperative chemotherapy and development of postoperative complications.
STUDY DESIGN - The study group consisted of 80 patients who underwent resection of CRCLM; half received neoadjuvant chemotherapy for 6 months before resection (n = 40) and the other half did not (n = 40). The study group was compared with two control groups: a normal group composed of patients undergoing cholecystectomy for benign disease (n = 40) and a group of untreated, nonmetastatic colorectal cancer (CRC) patients (n = 40). Splenic volume was measured by CT/MRI volumetry. In the study group, the nontumoral liver was graded for steatosis and sinusoidal injury; operative and outcomes characteristics were also analyzed.
RESULTS - Before chemotherapy, CRCLM patients had normalized spleen volumes of 3.2 ± 1.1 mL/kg, significantly higher than normal (2.5 ± 0.8 mL/kg; p < 0.001) and nonmetastatic CRC (2.6 ± 1.3 mL/kg; p < 0.05) patients, with higher splenic volume after 6 months of chemotherapy (4.2 ± 1.7 mL/kg; p < 0.01). After chemotherapy, splenic volume increase was associated with any perioperative complication (p < 0.01) and major complications (p < 0.05). Patients with ≥39% splenic volume increase (maximal chi-square test) were significantly more likely to have major complications (p < 0.01). Spleen volume changes were not correlated with change in platelet count (R(2) = 0.03; p = 0.301).
CONCLUSIONS - In patients with CRCLM, the presence of liver metastases and chemotherapy are associated with higher splenic volume. Percent splenic volume increase after 6 months of chemotherapy can aid preoperative risk stratification, as it was an independent predictor of major postoperative complications.
Copyright © 2015 American College of Surgeons. Published by Elsevier Inc. All rights reserved.
0 Communities
1 Members
0 Resources
22 MeSH Terms
Castleman disease in a pediatric liver transplant recipient: a case report and literature review.
Bonatti HJ, Axt J, Hunter EB, Lott SL, Frangoul H, Gillis L, Correa H, Kelly B
(2012) Pediatr Transplant 16: E229-34
MeSH Terms: Adolescent, Adult, Antigens, CD20, B-Lymphocytes, CD3 Complex, Castleman Disease, Graft Survival, Herpesvirus 8, Human, Humans, Immunosuppressive Agents, Infant, Newborn, Liver Failure, Liver Transplantation, Lymphatic Diseases, Male, Middle Aged, Polymerase Chain Reaction, Sirolimus, Splenomegaly, T-Lymphocytes, Tacrolimus, Tomography, X-Ray Computed
Show Abstract · Added March 27, 2014
Castleman disease is a rare hematologic disorder, closely linked to the HHV-8, and most commonly observed in immunocompromised individuals. Thirteen months following a liver transplant for CPS-1 defect, a 15-month-old boy presented with fevers, anemia, and growth retardation. Abdominal CT scan showed splenomegaly and generalized lymphadenopathy. Histology of chest wall lymph nodes revealed a mixed CD3+ T-cell and CD20+ B-cell population with atretic germinal centers consistent with multicentric Castleman disease. Qualitative DNA PCR detected HHV-8 in the resected lymph node and in the blood, supporting the diagnosis. Immunosuppression was tapered, and he was transitioned from tacrolimus to sirolimus. His graft function remained stable, and repeat imaging showed regression of the lymphadenopathy. The child is living one yr after Castleman disease diagnosis with a well-functioning graft. Castleman disease is a potential complication of solid organ transplant and HHV-8 infection. Reduction in immunosuppression and switch to sirolimus may be an effective strategy to treat this condition.
© 2011 John Wiley & Sons A/S.
0 Communities
1 Members
0 Resources
22 MeSH Terms
Thrombocytopenia is more severe in patients with advanced chronic hepatitis C than B with the same grade of liver stiffness and splenomegaly.
Tejima K, Masuzaki R, Ikeda H, Yoshida H, Tateishi R, Sugioka Y, Kume Y, Okano T, Iwai T, Gotoh H, Katoh S, Suzuki A, Koike Y, Yatomi Y, Omata M, Koike K
(2010) J Gastroenterol 45: 876-84
MeSH Terms: Adult, Aged, Blood Platelets, Carcinoma, Hepatocellular, Cohort Studies, Female, Hepatitis B, Chronic, Hepatitis C, Chronic, Humans, Liver Cirrhosis, Liver Neoplasms, Male, Middle Aged, Severity of Illness Index, Splenomegaly, Thrombocytopenia
Show Abstract · Added May 2, 2014
BACKGROUND AND AIM - The mechanism responsible for thrombocytopenia in chronic liver diseases (CLD) is not yet fully understood. The prevalence of thrombocytopenia has been reported to be higher in patients with hepatitis C virus-related hepatocellular carcinoma (CLD-C) than in those with hepatitis B virus-related hepatocellular carcinoma (CDC-B). We have examined the potential difference in thrombocytopenia between patients with CLD-B and those with CLD-C in terms of liver fibrosis adjustment and splenomegaly.
METHODS - The study cohort consisted of 102 patients with CLD-B and 143 patients with CLD-C were enrolled. Liver stiffness, which is reported to be well correlated with the degree of liver fibrosis, was measured by transient elastography.
RESULTS - The analysis of covariance with liver stiffness as a covariate revealed that the platelet count was lower in CLD-C patients than in CLD-B patients. Following stratification for liver stiffness, thrombocytopenia was found to be more severe in CLD-C patients than CLD-B patients with advanced liver stiffness, whereas the degree of splenomegaly was not significantly different. The plasma thrombopoietin level was not different between CLD-B and CLD-C patients with advanced liver stiffness, and the immature platelet number was lower in CLD-C patients despite thrombocytopenia being more severe in these patients.
CONCLUSIONS - CLD-C patients with advanced liver stiffness presented with more severe levels of thrombocytopenia than CLD-B patients even with the same grade of splenomegaly. Impaired platelet production rather than enhanced platelet destruction may underlie the mechanism responsible for thrombocytopenia in patients with CLD.
0 Communities
1 Members
0 Resources
16 MeSH Terms